Herantis Pharma PLC · OMXHEX:HRTIS
Herantis Pharma — Investor Day (March 2020)
26 slides from Herantis Pharma's investor day presentation, Mar 24, 2020
Slide 1: Toward clinical breakthroughs based on leading science
Toward clinical breakthroughs based on leading science Capital Markets Day Webcast 24 March 2020 Pekka Simula, CEO Dr. Henri Huttunen, CSO Dr. Antti Vuolanto, COO www.herantis.com © 2014-2020 HERANTIS PHARMA Plc. All rights reserved.
Slide 2: Disclaimer
Disclaimer • This presentation does not intend to provide a thorough and detailed view of Herantis Pharma Plc (‘Company’). The information provided in this presentation shall not be considered sufficient for making any investment decisions related to the Company. Anyone considering an investment in
Slide 3: Breaking the boundaries of standard therapeutic approaches
Breaking the boundaries of standard therapeutic approaches 3 www.herantis.com © 2014-2020 HERANTIS PHARMA Plc. All rights reserved.
Slide 4: Herantis aims at breakthroughs in unmet clinical needs
Herantis aims at breakthroughs in unmet clinical needs Parkinson’s disease (PD) Secondary lymphedema PD is an incurable brain disease whose first symptoms include tremors, muscle stiffness ○ Symptoms grow worse with disease progression ○ Known drugs only treat motor symptoms, only for a while Lymphe
Slide 5: Parkinson's facts and Lymphedema facts
Parkinson’s facts: Lymphedema facts: • Second most common • 140 million LE patients neurodegenerative disease: • 2 million breast cancer 7-10 million patients diagnosis annually • Estimated annual financial burden of PD is $50 billion → 30% of patients who undergo mastectomy will develop • Progressi
Slide 6: By developing disease-modifying treatments we fight both human suffering and societal costs
By developing disease-modifying treatments we fight both human suffering and societal costs 6 www.herantis.com © 2014-2020 HERANTIS PHARMA Plc. All rights reserved.
Slide 7: CDNF has the potential to change Parkinson's disease
CDNF has the potential to change Parkinson’s disease: Protection and restoration of dopaminergic (DA) neurons • CDNF helps stressed or injured neurons survive and recover • Mechanisms relevant to PD • Promising data in several neurological diseases 7 www.herantis.com © 2014-2020 HERANTIS PHARMA Plc.
Slide 8: CDNF doubled the number of DA neurons in a PD model
CDNF doubled the number of DA neurons in a PD model* Vehicle 150 µg CDNF 80% loss of dopaminergic neurons Doubled the number of dopaminergic neurons • Disease model: MPTP lesion model in aged Rhesus monkey • Three monthly CDNF doses doubled the number of DA neurons • Significant improvement in gross
Slide 9: CDNF may change how patients live with PD
CDNF may change how patients live with PD CDNF is in Phase 1-2 clinical study funded by EU: “Leading science, greatest potential to advance clinical practice” Ø Study fully recruited: 17 patients randomized in CDNF vs. placebo groups Ø First-in-human study in advanced PD patients à Primary endpoint
Slide 10: CDNF Phase 1-2 study has completed first 6 months of treatment
CDNF Phase 1-2 study has completed first 6 months of treatment: Initial conclusions • Primary endpoint met: CDNF is safe and well tolerated in advanced PD patients ○ Similar safety profile in placebo and CDNF dose groups • The study uses DAT-PET imaging as a surrogate biomarker for disease progressi
Slide 11: Planned next step: Phase 2 in earlier stage Parkinson's patients
Planned next step: Phase 2 in earlier stage Parkinson’s patients Hypothesis explained in Untreated Treatment start at 10 y after symptom onset 50 50 the pictures: 70 DA neurons left (%) 70 DA neurons left (%) UPDRS part III (off) UPDRS part III (off) DA neurons left (%) 60 40 DA neurons left (%) UPD
Slide 12: Next generation: xCDNF
Next generation: xCDNF • Common challenge in central nervous system diseases is drug delivery to the brain à CDNF is dosed with a sophisticated medical device • We have shown that certain fragments of CDNF: 1. Retain its biological activity (comparable efficacy in PD models) 2. Penetrate the BBB à n
Slide 13: xCDNF lead optimization: Exciting progress
xCDNF lead optimization: Exciting progress Dopamine neuron survival 125 • We have developed novel xCDNF compounds that Number of TH+ cells ** ** * (% of control) (1) have the cell-protective activity of CDNF, 100 Improvement (2) are metabolically stabilized, and 75 (3) can effectively penetrate the
Slide 14: Lymfactin gene therapy aims at curing secondary lymphedema
Lymfactin® gene therapy aims at curing secondary lymphedema 14 14 www.herantis.com © 2014-2020 HERANTIS PHARMA Plc. All rights reserved.
Slide 15: Lymfactin: VEGF-C gene therapy to reconstitute the lymphatic system
Lymfactin®: VEGF-C gene therapy to reconstitute the lymphatic system 1. A single Lymfactin® injection results in local VEGF-C expression for about 2 weeks 2. VEGF-C is the natural human protein that promotes the growth of lymphatic capillaries 3. Lymphatic capillaries mature into functional lymphati
Slide 16: Lymfactin development
Lymfactin® development • Phase 2 study AdeLE: recruitment completed, and all treatments concluded, in patients with breast cancer associated LE (BCAL) ○ Adjunct to lymph node transplantation surgery, which aims to relieve symptoms ○ Study centers: 5 university hospitals in Sweden and Finland • Safet
Slide 17: Planned next step with Lymfactin: Pivotal Phase 3
Planned next step with Lymfactin®: Pivotal Phase 3 • Tentative plan for a Pivotal Phase 3 clinical trial: ○ Target indication: Same as in the ongoing Phase 2 and previous Phase 1: Single-dose Lymfactin® as an adjunct to lymph node transplantation surgery ○ Randomization: 1:1 in Lymfactin® and placeb
Slide 18: Lymphedema: Market and awareness
Lymphedema: Market and awareness • 140 million LE patients worldwide • €600M market estimated for Lymfactin® as adjunct BCAL therapy ○ Significant potential in other lymphedemas • Lymphedema awareness increases ○ Herantis is a partner of LE&RN, international patient advocacy group ○ Hollywood supers
Slide 19: Herantis' Outlook for 2020 remains unaffected by the COVID-19 pandemic
Herantis’ Outlook for 2020 remains unaffected by the COVID-19 pandemic 1919 3/23/20 www.herantis.com www.herantis.com © 2014-2020 © 2014-2020 HERANTISHERANTIS PHARMAPHARMA Plc. AllPlc. All rights rights reserved. reserved.
Slide 20: It is easy for Herantis to act responsibly under an outbreak
It is easy for Herantis to act responsibly under an outbreak: Working remotely is in the genes of a ‘virtual biotech’ • Collaboration with international partners and subcontractors is always mainly managed remotely • Herantis already had “Virtual morning coffee” three times a week • Under the outbre
Slide 21: Herantis' clinical studies have completed almost all treatments
Herantis’ clinical studies have luckily completed almost all treatments • Phase 2 study AdeLE: Lymfactin® in breast cancer associated lymphedema ○ All patient treatments with Lymfactin® or placebo were completed in Dec 2019 ○ Study is now in the blinded 12-month follow-up until Dec 2020 ○ Little or
Slide 22: Herantis' Outlook for 2020 remains unchanged
Herantis’ Outlook for 2020 remains unchanged With a successful funding round completed just three months ago in Dec 2019, Herantis looks forward to 2020 from a position of strength • Herantis’ long-term goal is to significantly increase its business through commercialization agreements for its drug
Slide 23: Summary
Summary 23 www.herantis.com © 2014-2020 HERANTIS PHARMA Plc. All rights reserved.
Slide 24: CDNF and Lymfactin are in placebo-controlled studies that target significant unmet needs
CDNF and Lymfactin® are in placebo-controlled studies that target significant unmet needs 24 www.herantis.com © 2014-2020 HERANTIS PHARMA Plc. All rights reserved.
Slide 25: Herantis Pharma
Herantis Pharma • Targeting disease-modifying breakthroughs in significant unmet medical needs • Programs based on internationally renowned science published in Nature and Science • Approaching important milestones in two randomized clinical studies 25 www.herantis.com © 2014-2020 HERANTIS PHARMA Pl
Slide 26: Thank you
Thank you For more information please contact: Pekka Simula, CEO pekka.simula@herantis.com +358 40 7300 445 26 www.herantis.com © 2014-2020 HERANTIS PHARMA Plc. All rights reserved.